pharmaquotient.com

60 POSTS0 COMMENTS

http://pharmaquotient.com

Merger & Acquisition

Merck Acquired Harpoon Therapeutics, Inc.

pharmaquotient.com - 11 March 2024 0

Appointments

Robert A. Michael Has Been Named Chief Executive Officer by AbbVie

pharmaquotient.com - 20 February 2024 0

Merger & Acquisition

Bristol Mayers Squibb Agrees to Acquire Mirati Therapeutics to Diversify its Oncology Portfolio for up to $5.8 B

pharmaquotient.com - 8 October 2023 0

Clinical update

Novartis Announced Positive Phase III Results of Iptacopan in Proteinuria Reduction

pharmaquotient.com - 2 October 2023 0

Merger & Acquisition

Novartis Divests front of eye Ophthalmic Assets to Bausch+Lomb

pharmaquotient.com - 29 September 2023 0

generic

Sandoz Received EU Approval of Tyruko® (natalizumab) for multiple sclerosis in Europe

pharmaquotient.com - 26 September 2023 0

Regulatory update

Abbvie Announces EU Approval of Tepkinly (epcoritamab) for Adults with R/R Diffuse Large B-cell Lymphoma

pharmaquotient.com - 25 September 2023 0

Clinical update

Allergan Aesthetics Announces Positive Result from Phase 3 Study of OnabotulinumtoxinA (Botox cosmetics)

pharmaquotient.com - 18 September 2023 0

Clinical update

AbbVie’s SKYRIZI® (risankizumab) outdo Stelara® (ustekinumab) in Head-to-Head Study in Crohn’s Disease

pharmaquotient.com - 12 September 2023 0

Collaboration agreement

Otsuka and ShapeTX collaborates to develop novel AAV gene therapies for ocular diseases for up to $1.5B

pharmaquotient.com - 8 September 2023 0

1 234...6 Page 3 of 6

TOP AUTHORS

constance80t

0 POSTS0 COMMENTS

Neha Tripathi

1 POSTS0 COMMENTS

http://pharmaQuotient.com

pharma analyst

0 POSTS0 COMMENTS

pharmaquotient.com

60 POSTS0 COMMENTS

http://pharmaquotient.com

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

20 September 2024

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

17 September 2024

Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.

9 September 2024

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

7 September 2024

pharmaquotient.com

TOP AUTHORS

Most Read

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

EDITOR PICKS

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.

POPULAR POSTS

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.

POPULAR CATEGORY

ABOUT US

FOLLOW US